Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients

Salim Yusuf (Thu,) studied this question.

www.synapsesocial.com/papers/69d56ec075589c71d767d5c9 — DOI: https://doi.org/10.1056/nejm200001203420301

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction· 1995 · 1,774 citations
2. Co-expression of renin-angiotensin system genes in human adipose tissue· 1999 · 236 citations
3. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients· 1994 · 3,123 citations
4. Underestimation of Risk Associations Due to Regression Dilution in Long-term Follow-up of Prospective Studies· 1999 · 864 citations
5. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials· 1995 · 1,538 citations